BioRestorative Therapies, Inc. announced that it has been awarded a Small Business Technology Transfer (STTR) Phase I grant for $256,000 to evaluate the therapeutic effects on the company’s hypoxic cultured bone marrow derived MSCs after encapsulation with a PEG-peptide hydrogel.
[BioRestorative Therapies, Inc. (Globe Newswire, Inc.)]
7992332
{7992332:BBBBBBBB}
apa
50
1
170257
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
